Philip Morris International Inc. PM
Composite 57/100; the shares have moved about 31% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 33/100 — a moderate mark against it.
Quality ranks 70/100 — a moderate point in its favour. Income ranks 70/100 — a moderate point in its favour. Growth ranks 65/100 — a moderate point in its favour.
Valuation ranks 33/100 — a moderate mark against it.
What the company does Philip Morris International Inc. (PM) designs, manufactures, markets and sells cigarettes and smoke-free products worldwide under brands like IQOS, VEEV and ZYN, alongside accessories and wellness products. Its portfolio spans heat-not-burn devices, e-vapor, oral nicotine pouches and traditional tobacco.
Key financials PM posts gross margin 67.5%, operating margin 40.0% and net margin 25.6%. Revenue grew 7.3% and EPS 50.6% year-over-year. Dividend yield is 3.0% with a 72.6% payout ratio. Debt/Equity is –5.72 and net debt/EBITDA is 2.39.
Stock health SideraVIA scores: Overall 56.7 (Strong quality, richly valued), Quality 70.4, Growth 65.6, Strength 52.0, Valuation 29.6, Momentum 64.6, Income 65.9. Piotroski F-Score is 7/9. RSI(14) is 57.50.
Price vs fair value The stock trades at a discount of 5.10% versus the analyst mean target of 203.80. - ZYN ULTRA FDA authorization strengthens smoke-free push (Zacks) - Altria partnership on manufacturing cited as efficiency booster (Zacks) - Recent Q2 results and new FDA pouch approvals highlighted as catalysts (Simply Wall St) - StockStory flags PM among “unpopular stocks that deserve a second chance” (StockStory)
Looking forward Forward P/E is 22.03 and PEG 1.37, suggesting moderate valuation relative to growth. Smoke-free portfolio momentum and margin stability remain key watchpoints. Analysts see upside to 203.80, implying ~5% potential from current price.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.